Amgen (AMGN): No Conclusion on Sensipar's Role in Death, Still Working with FDA

February 26, 2013 12:18 PM EST Send to a Friend
Amgen, Inc. (NASDAQ: AMGN) says there is no conclusion on Sensipar's role in death outlined by the FDA. The company said it was still working with the FDA on Sensipar development.

Comments were made by a spokesperson via email to Bloomberg.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, FDA, Insiders' Blog

Add Your Comment